Carnevale Claudio, Til-Pérez Guillermo, Arancibia-Tagle Diego J, Tomás-Barberán Manuel D, Sarría-Echegaray Pedro L
Servicio de Otorrinolaringología y Cirugía de Cabeza y Cuello, Hospital Universitario Son Espases, Palma de Mallorca, España.
Servicio de Otorrinolaringología y Cirugía de Cabeza y Cuello, Hospital Universitario Son Espases, Palma de Mallorca, España.
Acta Otorrinolaringol Esp (Engl Ed). 2019 Mar-Apr;70(2):80-88. doi: 10.1016/j.otorri.2018.02.006. Epub 2018 May 18.
The active transcutaneous bone conduction implant Bonebridge, is indicated for patients affected by bilateral conductive/mixed hearing loss or unilateral sensorineural hearing loss, showing hearing outcomes similar to other percutaneous bone conduction implants, but with a lower rate of complications. The aim of this study was to analyze the hearing outcomes in a series of 26 patients affected by conductive or mixed hearing loss and treated with Bonebridge.
26 of 30 patients implanted with Bonebridge between October 2012 and May 2017, were included in the study. We compared the air conduction thresholds at the frequencies 500, 1000, 2000, 3000, 4000Hz, the SRT50% and the percentage of correct answers at an intensity of 50dB with and without the implant.
"Pure tone average" with the implant was 34.91dB showing an average gain of 33.46dB. Average SRT 50% with the implant was 34.33dB, whereas before the surgery no patient achieved 50% of correct answers at a sound intensity of 50dB. The percentage of correct answers at 50dB changed from 11% without the implant to 85% with it. We only observed one complication consisting of an extrusion of the implant in a patient with a history of 2 previous rhytidectomies.
The hearing outcomes obtained in our study are similar to those published in the literature. Bonebridge represents an excellent alternative in the treatment of conductive or mixed hearing loss, and with a lower rate of complications.
主动式经皮骨传导植入物Bonebridge适用于双侧传导性/混合性听力损失或单侧感音神经性听力损失的患者，其听力结果与其他经皮骨传导植入物相似，但并发症发生率较低。本研究的目的是分析26例患有传导性或混合性听力损失并接受Bonebridge治疗的患者的听力结果。
纳入2012年10月至2017年5月间植入Bonebridge的30例患者中的26例。我们比较了植入物开启和关闭时在500、1000、2000、3000、4000Hz频率下的气导阈值、50%言语识别阈（SRT50%）以及在50dB强度下的正确答案百分比。
植入后“纯音平均值”为34.91dB，平均增益为33.46dB。植入后的平均SRT50%为34.33dB，而术前没有患者在50dB声强下能达到50%的正确答案。50dB时的正确答案百分比从无植入物时的11%变为有植入物时的85%。我们仅观察到1例并发症，发生在1例曾有2次除皱手术史的患者中，表现为植入物外露。
我们研究中获得的听力结果与文献报道的相似。Bonebridge是治疗传导性或混合性听力损失的极佳选择，且并发症发生率较低。
